Lenalidomid Alkaloid-Int

Lenalidomide, the active ingredient in Lenalidomid Alkaloid-Int, is an immunomodulatory imide drug (IMiD) presented as an oral formulation for oral use. It is employed in the treatment of certain blood cancers, including multiple myeloma, myelodysplastic syndromes with del(5q), mantle cell lymphoma and follicular lymphoma, typically in adult patients.

GNH USA supplies Lenalidomid Alkaloid-Int as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies, clinics and research institutions worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution.

Lenalidomide is used in hematologic malignancies, targeting abnormal plasma cells and dysregulated bone‑marrow environments.

- Multiple myeloma: improves survival and disease control in patients with relapsed or refractory disease. - Myelodysplastic syndromes (del(5q)): reduces transfusion dependence and corrects cytopenias. - Mantle cell lymphoma: induces remission and prolongs progression‑free survival. - Follicular lymphoma: enhances response rates when combined with other therapies.

Lenalidomide may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require fluid replacement. - Rash: mild to moderate skin eruptions. - Constipation: reduced bowel movements causing discomfort.

Serious or Rare Side Effects: - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly low neutrophil counts increasing infection risk. - Secondary malignancies: emergence of new cancers unrelated to the primary disease.

Lenalidomide requires careful monitoring and patient education before initiation.

- Pregnancy risk: avoid use in pregnant women; effective contraception is mandatory for women of child‑bearing potential. - Thrombosis prophylaxis: assess need for anticoagulation in patients with additional risk factors. - Renal function: dose adjustment may be needed in patients with impaired kidney function. - Hepatic impairment: monitor liver enzymes and adjust therapy as clinically indicated. - Store at ambient temperature: keep below 25 °C, protect from moisture, and retain in original packaging.

Lenalidomide can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce plasma concentrations of lenalidomide. - Anticoagulants (e.g., warfarin): increased risk of bleeding when combined.

Moderate Interactions (Monitor Closely): - P‑glycoprotein inhibitors (e.g., verapamil): may raise lenalidomide exposure. - Immunosuppressants (e.g., cyclosporine): heightened risk of infection. - Vaccines: live attenuated vaccines should be avoided during therapy.